Literature DB >> 22054730

Chronic myeloid leukemia: mechanisms of resistance and treatment.

Elias Jabbour1, Sameer A Parikh, Hagop Kantarjian, Jorge Cortes.   

Abstract

Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22054730      PMCID： PMC4428141          DOI： 10.1016/j.hoc.2011.09.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  53 in total

1.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

2.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

3.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

4.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Authors:  Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

5.  Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

Authors:  Hagop M Kantarjian; Richard A Larson; Francois Guilhot; Stephen G O'Brien; Manisha Mone; Marc Rudoltz; Tillmann Krahnke; Jorge Cortes; Brian J Druker
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

Review 6.  Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.

Authors:  A Hochhaus; P La Rosée
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

7.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

Review 8.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Authors:  Gianantonio Rosti; Francesca Palandri; Fausto Castagnetti; Massimo Breccia; Luciano Levato; Gabriele Gugliotta; Adele Capucci; Michele Cedrone; Carmen Fava; Tamara Intermesoli; Giovanna Rege Cambrin; Fabio Stagno; Mario Tiribelli; Marilina Amabile; Simona Luatti; Angela Poerio; Simona Soverini; Nicoletta Testoni; Giovanni Martinelli; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Journal:  Blood       Date:  2009-10-12       Impact factor: 22.113

10.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Authors:  Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Marina Konopleva; Alessandra Ferrajoli; Tapan Kadia; Gautam Borthakur; Denise Stigliano; Jianqin Shan; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544
View more
  15 in total

1.  Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.

Authors:  Vijaya L Damaraju; Dwayne Weber; Michelle Kuzma; Carol E Cass; Michael B Sawyer
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 2.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Authors:  Qiangui Bu; Lijing Cui; Juan Li; Xin Du; Waiyi Zou; Ke Ding; Jingxuan Pan
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

Review 4.  Protein phosphatase 2A: a target for anticancer therapy.

Authors:  Danilo Perrotti; Paolo Neviani
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

Review 5.  Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Authors:  Aritro Nath; Jacqueline Wang; R Stephanie Huang
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

Review 6.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 7.  The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Priyanka A Pophali; Mrinal M Patnaik
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360

Review 8.  ABCB1 genetic variants in leukemias: current insights into treatment outcomes.

Authors:  Ravindran Ankathil
Journal:  Pharmgenomics Pers Med       Date:  2017-05-12

9.  Olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid (OEOA) induces G1 cell cycle arrest and differentiation in human leukemia cell lines.

Authors:  Yu Pong Ng; Yuewen Chen; Yueqing Hu; Fanny C F Ip; Nancy Y Ip
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

10.  Compositions and anti-tumor activity of Pyropolyporus fomentarius petroleum ether fraction in vitro and in vivo.

Authors:  Yanhua Zhang; Yaping Xiao; Pan Wang; Quanhong Liu
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.